UPB (Upstream Bio) Revenue: $3.32 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

UPB Upstream Bio Inc UPB
10 GF Score
Price $6.99
! 1 Warning Sign
View Full Analysis

What is Upstream Bio Revenue?

Upstream Bio UPB -3.04% 10 Revenue is $3.32 Mil as of Mar. 2026. GuruFocus rates UPB with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

Upstream Bio's revenue for the three months ended in Mar. 2026 was $1.03 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $3.32 Mil. Upstream Bio's Revenue per Share for the three months ended in Mar. 2026 was $0.02. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.06.

During the past 12 months, the average Revenue per Share Growth Rate of Upstream Bio was 38.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 17.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 4 years, Upstream Bio's highest 3-Year average Revenue per Share Growth Rate was 17.10% per year. The lowest was 17.10% per year. And the median was 17.10% per year.

Upstream Bio  (NAS:UPB) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Upstream Bio Revenue Related Terms

Upstream Bio Revenue Historical Data

* Premium members only.

The historical data trend for Upstream Bio's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Upstream Bio Revenue Chart

Upstream Bio Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Revenue
1.21 2.38 2.37 2.85

Upstream Bio Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.94 0.68 0.67 1.03

UPB vs OABI, VNDA, LXEO: Revenue Comparison

For the Biotechnology subindustry, Upstream Bio's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Upstream Bio Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Upstream Bio's Revenue distribution charts can be found below:

* The bar in red indicates where Upstream Bio's Revenue falls into.


UPB
10GF Score
Upstream Bio Inc UPB
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Upstream Bio Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $3.32 Mil mean?
Upstream Bio (UPB) has a Revenue of $3.32 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Upstream Bio and its competitors.
Is Upstream Bio's Revenue too high?
Upstream Bio's current Revenue is $3.32 Mil. Overall, Upstream Bio has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Upstream Bio's Revenue compare to OABI and VNDA?
Upstream Bio's Revenue of $3.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Upstream Bio and its competitors. Upstream Bio's current Revenue is $3.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Upstream Bio stock overvalued right now?
Upstream Bio (UPB) has a current Revenue of $3.32 Mil. The current Revenue is $3.32 Mil. Upstream Bio's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Upstream Bio (UPB), the current Revenue is $3.32 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Upstream Bio Business Description

Address 890 Winter Street, Suite 200, Waltham, MA, USA, 02451
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
10GF Score

Get the complete analysis for UPB

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.99
Price